André Bosly
About
In The Last Decade
André Bosly
184 papers receiving 9.4k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Pathology and Forensic Medicine 5.8k
- Oncology 4.8k
- Genetics 2.4k
- Hematology 2.0k
- Neurology 1.9k
Countries citing papers authored by André Bosly
This map shows the geographic impact of André Bosly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Bosly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Bosly more than expected).
Fields of papers citing papers by André Bosly
This network shows the impact of papers produced by André Bosly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Bosly. The network helps show where André Bosly may publish in the future.
Co-authorship network of co-authors of André Bosly
This figure shows the co-authorship network connecting the top 25 collaborators of André Bosly. A scholar is included among the top collaborators of André Bosly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André Bosly. André Bosly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era breakdown → | 1117 |
| 2 | 50 | |
| 3 | A Phase Ii International, Multicenter Study of Oral Panobinostat (lbh589) in Patients With Refractory Cutaneous T-cell Lymphoma (ctcl) | 1 |
| 4 | New 9p24 abnormalities in hematological malignancies | 1 |
| 5 | Impact of photochemical treatment (intercept) on platelet use in routine practice | 1 |
| 6 | Recombinant urate oxidase (Rasburicase) is safe and effective in managing hyperuricemia in children and adults: Results of a multi-national compassionate use trial. | 2 |
| 7 | 30 | |
| 8 | Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study. | 5 |
| 9 | Cytogenetic remissions in high-risk myelodysplastic syndrome: Results in 124 patients treated with low-dose 5-aza-2 '-deoxycytidine (Decitabine), a DNA methylation inhibitor. | 3 |
| 10 | Late intensification is superior to early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma. A randomized study from the GELA: LNH RP93. | 1 |
| 11 | Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia | 42 |
| 12 | Alternance of chemotherapy does not improve results in aggressive non-Hodgkin's lymphoma: A prospective randomized study on 884 patients LNH87 protocol group 3: A gela study | 2 |
| 13 | Rapid Diagnosis of Cerebral Toxoplasmosis By Pcr in Allogeneic Bmt Leads To Early and Successful Treatment | 0 |
| 14 | 2-chlorodeoxyadenosine (cda) for Previously Untreated Chronic Lymphocytic-leukemia (cll) | 3 |
| 15 | 2-chloro-deoxyadenosine With Or Without Daunorubicin for Relapsing Or Refractory Acute Myeloblastic-leukemia | 1 |
| 16 | Le traitement des rechutes de lymphomes. | 0 |
| 17 | Phase-i High-dose Alkylating Agent Association of Cyclophosphamide, Bcnu and Melphalan With Abmt | 1 |
| 18 | Plasma-exchange in Waldenstroms Disease - Efficacy and Comparison of Continuous Centrifugation, Discontinuous Centrifugation, and Filtration | 2 |
| 19 | Translocation-t(6,9) in a Case of Multiple-myeloma | 1 |
| 20 | Late Intensification Chemotherapy and Autologous Bone-marrow Transplantation in Small Cell Lung-cancer | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.